Pilgeram, L; Pickart, L (1968). “Control of fibrinogen biosynthesis; the role of free fatty acids”. J Atheroscler Res8: 155–166. doi:10.1016/s0368-1319(68)80089-4.
Schlesinger, DH; Pickart, L; Thaler, MM (1977). “Growth-modulating serum tripeptide is glycyl-histidyl-lysine”. Cellular and Molecular Life Sciences33 (3): 324–325. doi:10.1007/BF02002806.
Mulder GD, Patt LM, Sanders L et al (1994). “Enhanced healing of ulcers in patients with diabetes by topical treatment of glycyl-l-histidyl-l-lysine”. Wound Repair Regen2 (4): 259–269. doi:10.1046/j.1524-475X.1994.20406.x. PMID17147644.
Bishop, JB; Phillips, LG; Mustoe, TA; et al (Aug 1992). “A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers”. J Vasc Surg16 (2): 251–257. doi:10.1016/0741-5214(92)90115-o. PMID1495150.
Johnson, Wilbur; Bergfeld, Wilma F.; Belsito, Donald V.; et al (2018). “Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics”. International Journal of Toxicology37 (3_suppl): 90–102. doi:10.1177/1091581818807863.
Pickart, L; Thaler, MM (1973). “Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver”. Nature New Biology243 (124): 85–87. PMID4349963.
Mulder GD, Patt LM, Sanders L et al (1994). “Enhanced healing of ulcers in patients with diabetes by topical treatment of glycyl-l-histidyl-l-lysine”. Wound Repair Regen2 (4): 259–269. doi:10.1046/j.1524-475X.1994.20406.x. PMID17147644.
Bishop, JB; Phillips, LG; Mustoe, TA; et al (Aug 1992). “A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers”. J Vasc Surg16 (2): 251–257. doi:10.1016/0741-5214(92)90115-o. PMID1495150.